. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: Breast Cancer Res Treat. 2012 Dec 16;137(2):10.1007/s10549-012-2373-1. doi: 10.1007/s10549-012-2373-1

Table 5.

Multivariate analysis for the effect of PTP1B on OS

Clinicopathologic parameter	Hazard ratio (95 % CI)	p value
PTPB1 = 0 % (reference)	1
PTP1B ≥5 %	0.779 (0.651–0.930)	0.006
Age (per 1-year)	1.037 (1.030–1.045)	<0.001
Tumor grade
BRE grade 1 (reference)	1
2	1.622 (1.227–2.145)	<0.001
3	2.614 (1.955–3.495)	<0.001
Tumor stage
pT1 (reference)	1
pT2	1.6523 (1.272–2.147)	<0.001
pT3	2.139 (1.483–3.086)	<0.001
pT4	2.375 (1.713–3.291)	<0.001
Lymph node stage
pN1 (reference)	1
pN1	1.378 (1.130–1.681)	<0.001
pN2	2.634 (1.997–3.475)	0.002
Molecular subtype
Luminal A (reference)	1
Luminal B (HER2^–)	1.086 (0.801–1.474)	0.594
Luminal B (HER2⁺)	1.3 (0.893–1.894)	0.171
HER2 type	1.207 (0.800–1.821)	0.369
Basal-like	1.871 (1.319–2.654)	<0.001

However, PTP1B expression did have a positive effect on OS in ER⁺ cases (HR = 0.693, p < 0.001), but not in ER^– cases (HR = 1.082, p = 0.733) (Table 4; Fig. 4).